X

Trial Profile

A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diacerein (Primary)
Indications Haemophilia A; Haemophilia B; Haemophilic arthropathy; Joint disorders
Focus Proof of concept; Therapeutic Use
Sponsors TWi Biotechnology

Most Recent Events

07 Jul 2020 Status changed from active, no longer recruiting to completed.
15 Nov 2018 According to a TWi Biotechnology media release, the Company expects to release top-line results from the interim analysis of this study in the second quarter of 2019.
15 Nov 2018 Status changed from recruiting to active, no longer recruiting, as reported in a TWi Biotechnology media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com